Alpha Tau to Participate in May Investor Conferences
Upcoming Investor Conferences: Alpha Tau Medical Ltd. will have CFO Raphi Levy presenting at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, and participating in 1x1 meetings at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025.
About Alpha Tau Medical: Founded in 2016, Alpha Tau focuses on developing the Alpha DaRT therapy for treating solid tumors, utilizing a method that delivers alpha radiation directly to tumors while minimizing damage to surrounding healthy tissue.
Get Free Real-Time Notifications for Any Stock
Analyst Views on DRTSW
No data
About the author
Alpha Tau Achieves First Patient Treatment in U.S. Multi-Center Clinical Trial for Pancreatic Cancer
Pilot Study Initiation: Alpha Tau Medical has commenced a multi-center pilot study, IMPACT, to evaluate the safety and efficacy of Alpha DaRT combined with chemotherapy for patients with newly diagnosed unresectable pancreatic adenocarcinoma, a condition affecting up to 87% of patients at diagnosis.
Innovative Treatment Approach: The study aims to provide a localized treatment option using Alpha DaRT's targeted alpha radiation, potentially improving outcomes for patients with limited treatment options, while continuing their standard chemotherapy regimen.
Alpha Tau to Attend Five Investor Conferences in September
Company Announcement: Alpha Tau Medical Ltd. announced that CFO Raphi Levy will present at five investor conferences in September 2025, focusing on their innovative cancer therapy, Alpha DaRT.
Alpha DaRT Technology: The Alpha DaRT platform utilizes localized alpha particle radiotherapy to target solid tumors while minimizing damage to surrounding healthy tissue, with promising immuno-stimulatory effects.
Upcoming Conferences: Key events include the Citi 2025 Biopharma Summit, H.C. Wainwright Global Investment Conference, and others, where Mr. Levy will be available for one-on-one meetings with investors.
Forward-Looking Statements: The press release contains forward-looking statements regarding clinical trials and regulatory approvals, highlighting uncertainties and potential risks associated with the company's future performance.